Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05841160 · ClinicalTrials.gov registry record · Phase 1
Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization
A Phase 1 study, sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT05841160 is a Phase 1 study that has completed, run by Emalex Biosciences. The registered enrollment target is 29 participants.
The verdict
NCT05841160, a Phase 1 study, has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
THOROUGH QT/QTc STUDY TO EVALUATE THE EFFECTS OF ECOPIPAM (EBS-101) ON CARDIAC REPOLARIZATION
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG Ecopipam Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2023-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05841160
The ClinicalTrials.gov registry entry for NCT05841160 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emalex Biosciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05841160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05841160 about?
NCT05841160 is a clinical study titled "Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization". THOROUGH QT/QTc STUDY TO EVALUATE THE EFFECTS OF ECOPIPAM (EBS-101) ON CARDIAC REPOLARIZATION
What is the current status of trial NCT05841160?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2023-03-15. Estimated completion is 2023-05-12.
What interventions are being tested in trial NCT05841160?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), Ecopipam Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05841160?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.